Summary
Merck & Co., Inc. (MRK) reported strong revenue growth in the second quarter of 2021, with total sales increasing by 22% year-over-year to $11.4 billion. This growth was primarily driven by robust performance in the Pharmaceutical segment, particularly from Keytruda in oncology, as well as strong sales of vaccines like Gardasil 9. The Animal Health segment also contributed positively with increased sales in both livestock and companion animal products. The company completed the significant spin-off of Organon & Co. in June 2021, which has been reflected as discontinued operations. Despite overall positive sales trends, research and development expenses significantly increased due to the acquisition of Pandion Therapeutics for $1.9 billion, alongside ongoing clinical development spending. The company also provided an update on its COVID-19 efforts, including the development of molnupiravir, an antiviral therapy for COVID-19, and manufacturing support for other vaccines. Merck continues to manage global pricing pressures and adapt to the evolving COVID-19 landscape.
Financial Highlights
52 data points| Revenue | $11.40B |
| Cost of Revenue | $3.10B |
| Gross Profit | $8.30B |
| R&D Expenses | $4.32B |
| SG&A Expenses | $2.28B |
| Operating Income | $3.96B |
| Interest Expense | $202.00M |
| Net Income | $1.54B |
| EPS (Basic) | $0.61 |
| EPS (Diluted) | $0.61 |
| Shares Outstanding (Basic) | 2.53B |
| Shares Outstanding (Diluted) | 2.54B |
Key Highlights
- 1Total sales for Q2 2021 increased 22% year-over-year to $11.4 billion, driven by strong Pharmaceutical and Animal Health segment performance.
- 2Keytruda (pembrolizumab) sales continued robust growth, up 23% in Q2 2021, supported by new indications and strong demand.
- 3Gardasil/Gardasil 9 vaccine sales surged by 88% in Q2 2021, reflecting recovery from COVID-19 impacts and strong demand.
- 4Merck completed the spin-off of its Organon & Co. business on June 2, 2021, with historical results now reflected as discontinued operations.
- 5Research and Development expenses more than doubled in Q2 2021 to $4.3 billion, largely due to the $1.9 billion acquisition of Pandion Therapeutics.
- 6The company is actively developing molnupiravir, an oral antiviral therapy for COVID-19, and has entered into a procurement agreement with the U.S. government.
- 7Ongoing pricing pressures in global healthcare markets continue to impact sales performance, particularly for diabetes products like Januvia and Janumet.